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T
reatment for inflammatory bowel
disease (IBD) frequently involves the
aggressive use of immunosuppressants
that increases susceptibility to and severity
of other infections. There is limited
knowledge of coverage and serologic
protection of routine immunizations. The
aim of this study was to evaluate serologic
protection to and completeness of routine
vaccinations in children with IBD. In
this single-center cross-sectional study,
children with IBD followed at the Alberta
Children’s Hospital were recruited from
September 15, 2011 to August 15, 2012. IBD
history, demographics, immunosuppressive
medication use, vaccination records, and
serum were evaluated. 155 children with
IBD underwent serum collection; complete
vaccine records were available for 152 of these
children. At enrollment, 93 participants
(60.0%) were using immunosuppressive
medications; an additional 30 participants
had a history of medical immunosuppression.
Only 69.7% of the participants had up to
date MMR (measles, mumps, and rubella),
DTap-IPV-Hib, and HBV immunizations.
Serologic protection was mounted by
20.6% (hepatitis A), 59.4% (mumps),
63.2% (hepatitis B), 64.5% (measles),
71.0% (varicella), 78.1% (rubella), 80.0%,
(diphtheria), and 81.3% (tetanus) of the
participants. Children with IBD are at
risk for vaccine-preventable illnesses due
to lack of receiving complete vaccine series
and mounting an inadequate serologic
response to vaccinations. Serologic
response to vaccinations was independent
of immunomodulator therapy, suggesting
that the altered immunocompetence is a
consequence of the IBD diagnosis. Therefore,
clinicians caring for patients with IBD
should be conscientious about adherence
to recommended vaccination schedules,
measurement of immune response to vaccines,
and administering booster vaccinations where
appropriate.
Introduction
Inflammatory bowel disease (IBD) is a chronic
relapsing and remitting condition of inflammation in
the gastrointestinal tract1. It is an immune-mediated
disease resulting from an inappropriate inflammatory
response to an environmental stimulus in a genetically
susceptible host2,3. It can be divided into two
subclasses; ulcerative colitis primarily affects the
mucosa of the large colon, while Crohn’s disease
causes patchy transmural inflammation of the entire
gut1,3. Though IBD affects individuals of all ages,
some of the manifestations unique to children include
severe malnutrition and impaired growth1. Per 100
000 children, IBD affects 70 with 4.7 new pediatric
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cases each year in North America and Western
Europe, the regions of highest prevalence1,4,5.
Treatment for IBD frequently involves the
use of potent immunosuppressants to reduce
intestinal inflammation, limit complications
and induce and maintain remission2. Specifically,
immunosuppressants, such as systemic corticosteroids
(prednisone, methylprednisolone, and budesonide),
immunomodulators (azathioprine, 6-mercaptopurine,
methotrexate, and thalidomide), calcineurin
inhibitors (tacrolimus and cyclosporin), and
anti-tumor necrosis factor alpha (anti-TNFα)
biologics (infliximab and adalimumab) effectively
treat and prevent flare-ups5. The choice of
therapy depends on the severity, behaviour, and
location of the disease, as well as any side effects
and adverse events from medical treatment3.
Increasingly, medical management has moved
towards earlier introduction of immunosuppressive
therapies and concomitant treatments6, however,
this more aggressive top-down regime of general
immunosuppression increases susceptibility to and
severity of opportunistic infections2,7.
The health care maintenance of
immunocompromised individuals is unique due to
the balance of protection against vaccine-preventable
disease and the risk of vaccine adverse events in
an immunosuppressed individual2,8. International
guidelines encourage immunosuppressed individuals
to adhere to the same vaccination schedules
recommended for the general population with live
agent vaccines as the only exception2,7. Attenuated
live vaccines, such as the varicella vaccine, need to
be administered a minimum of 3 weeks preceding
the start of immunosuppressive therapy6. Canada’s
universal health care plan provides all legal residents
free access to health services including routine
childhood immunizations9. The 7th edition of the
Canadian Immunization Guide provides specific
immunization recommendations for individuals who
are medically immunosuppressed9. The general
principles include:
1. Assume all individuals are susceptible except if
serologic tests prove otherwise.
2. Avoid immunizations during periods of altered
immunity. If appropriate, vaccination and
immunosuppression schedules should be modified
to optimize vaccine response.
3. Boost aggressively as altered immunocompetence
may decrease the magnitude and duration of
vaccine-induced protection.
4. Unless data is available to support their use,
postpone live attenuated vaccines until immune
function has improved due to the risks of
vaccine-associated infections.
However, in spite of these guidelines, many
individuals continue to postpone or refuse
immunizations due to lack of awareness, unstable
disease activity, or fear of disease exacerbation2. The
childhood immunization schedule varies between
provinces in Canada; the schedule for the province
of Alberta is outlined in Table 110.
In the last decade, additions to the Alberta
schedule included varicella (chickenpox) vaccine
(2001), pneumococcal conjugate vaccine
(pneumococcal conjugate vaccine - 7-valent:
2002, pneumococcal conjugate vaccine - 13-valent:
2010), meningococcal-C conjugate vaccine (2002),
meningococcal conjugate vaccine (Groups A, C,
W-135, and Y: 2011), and human papilloma virus
vaccine (2008)9.
Newly diagnosed patients with IBD often
inquire about the course of the disease and
expectations related to quality of life, therefore, it
is essential to understand the relationship between
immunosuppressant medical therapy, immune health,
and opportunistic infections3,5,11. In children
with IBD, the completeness of routine childhood
vaccinations along with the presence and duration
of serologic protection to routine childhood
vaccines are unknown. The relationship between
immunosuppressive therapy at time of or after
vaccination on serologic protection is also unknown.
Knowledge of the presence and duration of serologic
protection to immunizations in children with IBD
may help guide potential future recommendations
for routine and booster vaccinations to optimize
protection against vaccine- preventable illnesses7.
This information is especially important for children
with IBD at risk for increased incidence and severity
of infections due to medical immunosuppression. In
addition, knowledge of the trends for incomplete
vaccinations will be a valuable asset for health
care providers seeking to optimize vaccination
completeness in children with IBD. The objective
of this study was to evaluate the serologic protection
to and completeness of routine childhood vaccinations
in children with IBD.
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Methods
Participants
Participants for this single-center cross-sectional
study were recruited from September 15, 2011
to August 15, 2012 through the pediatric
Gastroenterology clinic at the Alberta Children’s
Hospital. Potential participants were identified
through nonprobability convenience sampling and
enrollled by mail, telephone, or in person at the
time of a visit. Individuals who had previously
participated in the 2008 study “Immunogenicity
and Safety of Influenza Vaccine in Children with
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Inflammatory Bowel disease” (Ethics ID 21876) were
also recruited. The inclusion criteria for the cohort
were a diagnosis of IBD established by accepted
criteria for endoscopy, histology, clinical course,
radiology, and surgery12 and age between 2 to
18 years. The exclusion criterion was parent or
legal guardian unwilling or unable to provide signed
informed consent. Participants were not paid to
participate.
Study Conduct
Demographic data and medical history were collected
from participants using a standardized questionnaire.
This included information about IBD history (IBD
type, date of diagnosis, and start and end date of all
IBD medications). The IBD medications considered
to be immunosuppressive included: systemic
corticosteroids (prednisone, methylprednisolone,
and budesonide), immunomodulators (azathioprine,
methotrexate, and thalidomide), calcineurin
inhibitors (tacrolimus and cyclosporin), and
anti-TNFα biologics (infliximab and adalimumab).
Data was also collected on infectious history for
varicella infection (date of infection and parental
recall versus physician diagnosis versus laboratory
confirmation) and risk factors for hepatitis B infection
(country of birth, ethnicity, history of jaundice or
liver disease, international travel, household exposure
to individuals with hepatitis B, blood transfusions,
percutaneous risk factors [intravenous drug use,
tattoos, and body piercings], and nosocomial risk
factors [needle stick injury]).
A copy of immunization records was obtained from
either the Public Health Clinic or from personal
immunization cards. A vaccine dose was considered
valid if the written record documented the type of
vaccine and date of administration. Invalid records
included parental recall without documentation of
the type and date of vaccine administration. Written
informed consent was attained to access immunization
records and medical record shadow charts from the
pediatric Gastroenterology clinic to confirm collected
data.
Serum was collected (3-5 mL in a gold-top
Vacutainer tube) from each participant to assess
for serologic protection. In addition to collecting
new serum from patients, consent was obtained from
participants who had previously participated in the
2008 study“Immunogenicity and Safety of Influenza
Vaccine in Children with Inflammatory Bowel disease”
(Ethics ID 21876) to use the residual serum volume
for testing.
Immunization Completeness
Patient immunization records were compared with
the routine immunization schedule provided by the
Government of Alberta Health and Wellness to
determine completeness of immunizations. Criterion
for up to date and age appropriate immunizations
were:10,12
• MMR-2 doses (at 12 months and 4 to 6 years)
• DTaP-IPV-Hib- 5 doses (at 2 months, 4 months,
6 months, 18 months, 1-6 years [except Hib])
• HBV- 3 doses (at grade 5 or 9 to 11 years)
• HAV- 2 doses (6-12 months apart)
• VZV- 1 dose (if aged 12 months to 12 years old)
or 2 doses (28 days apart if greater than 13 years
of age)
• PCV13- 1 dose (if greater than 23 months of age)
or 3 doses (if aged 2 to 23 months)
• Men C- 1 dose (if greater than 12 months of age)
or 2 doses ( if aged 2 to 12 months)
• HPV- 3 doses (females at grade 5 or 9 to 11 years
starting in 2008 or at grade 9 or 13 to 15 years
from 2009 to 2012)
In the last decade, the Albertan schedule added
the varicella virus (VZV) vaccine, pneumococcal
conjugate vaccine (PCV13), meningococcal-C
conjugate vaccine (Men C), and human papilloma
virus (HPV) vaccine, some of which were not part
of the immunization schedule for all participants.
The majority of these participants received vaccines
under the previous recommended immunization
schedule that only included the: 1) measles, mumps,
and rubella vaccine (MMR), 2) diphtheria, tetanus,
acellular pertussis, inactivated polio virus vaccine
and Haemophilus influenzae type b conjugate vaccine
(DTaP-IPV-Hib), and 3) hepatitis B vaccine (HBV).
These three vaccines constituted the standard
childhood immunizations for assessing completeness
of vaccinations.
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Serologic Protection
The Provincial Laboratory for Public Health
(Microbiology), Calgary, Alberta, stored the serum
at −20 ◦C and conducted the serologic testing13.
Antibodies to HBV surface antigen, hepatitis
A virus (HAV), VZV, measles, mumps, rubella,
Corynebacterium diphtheria toxin, and Clostridium
tetani toxin were measured by microparticle enzyme
immunoassays for the viruses. The assays for HAV,
VZV, measles, mumps, Corynebacterium diphtheria
toxin, and Clostridium tetani toxin were qualitatively
reported as positive, indeterminate, or negative; a
positive result indicated serologic protection. The
assays for rubella IgG antibody and antibody to
HBV surface antigen were quantitative and were
reported in IU/ml and IU/L, respectively. Serological
protection for rubella was indicated by a rubella
IgG titer ≥ 15 IU/ml and an antibody titer ≥
10 IU/L for hepatitis B surface antigen. The
laboratory technicians and virologists performed
the serologic testing without knowledge of the
participants diagnosis, immune status, or medical
treatment.
Statistical Analysis
Data was entered into a database with Excel XP
(Microsoft Corp, Redman, WA). We described
demographic characteristics, IBD history, and
immunization completeness. For each vaccine, the
proportion of children with IBD with serologic
protection was calculated. For vaccine completeness,
the proportion of children with IBD and complete
routine childhood vaccinations was evaluated.
Descriptive statistics were determined as medians
(with first quartile [Q1] and third quartile [Q3]) or
proportions where appropriate. Statistical tests were
two-sided with significance assigned at P<0.05.
The Alberta Childrens Hospital pediatric
Gastroenterology Clinic follows approximately 200
children with IBD. Attempts to contact all of these
children over the enrollment period were made by
mail, telephone, or clinic/hospital visit.
Results
Study Participants
There were 155 patients who enrollled in the study
and provided serum: 93 Crohn’s disease, 46 ulcerative
colitis, and 16 IBD-unclassified. Complete vaccine
records were available for 152 of these children. The
median age at enrollment was 15.9 years (Table 2).
Immunosuppressive Medication Use
At enrollment, 93 participants (60.0%) were on
immunosuppressive therapy: 20 participants (12.9%)
on systemic corticosteroids (15 on prednisone, 2
on methylprednisolone, and 3 on budesonide);
70 participants (45%) on immunomodulators (41
on azathioprine, 28 on methotrexate, and 1
on thalidomide); and 48 participants (31%)
on biologics therapy (45 on infliximab and
3 on adalimumab). Of these patients on
immunosuppressive therapy, 41 participants (44.1%)
were on combination therapy: 9 on corticosteroids
and immunomodulators; 2 on corticosteroids and
biologics; 26 on immunomodulators and biologics;
and 4 on corticosteroids, immunomodulators, and
biologics. Participants with Crohn’s disease (74.2%)
were more likely to be on immunosuppressants than
either ulcerative colitis (34.8%) or IBD- unclassified
(50.0%) (p<0.001).
A total of 123 participants (79.4%) reported
having ever used immunosuppressants: 105 used
systemic corticosteroids (104 used prednisone, 9 used
methylprednisolone, and 10 used budesonide); 98
used immunomodulators (88 used azathioprine, 43
used methotrexate, and 1 used thalidomide); and
59 used biologics (58 used infliximab and 3 used
adalimumab).
From review of the 152 vaccination records, the
proportion with complete series for each vaccine
according to the Alberta schedule (at age of
vaccination) was evaluated. 106 participants (69.7%)
had the standard immunizations up to date: 142
participants (93.4%) for MMR, 130 participants
(85.5%) for DTap-IPV-Hib, and 127 participants
(83.6%) for HBV (Table 3).
For the HPV vaccinations, 126 participants (82.9%)
did not receive the vaccine: 25 female participants
did not receive the vaccine, 20 female participants
were outside of the appropriate age bracket, and 82
male participants were excluded from the numbers
for HPV. Of note, 1 of the 82 male participants with
valid immunization documentation received the HPV
vaccine. For varicella, 60 participants received at
least one dose of varicella vaccine (55 participants
received 1 dose, 5 received 2 doses); 85 participants
had a history of chickenpox infection (51 participants
reported diagnoses by a physician and 10 cases were
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confirmed by a blood test). However 10 of 152
participants had neither been infected nor vaccinated,
including 7 participants who were currently using
immunosuppressive medications. Whether or not
the participants received immunosuppressive therapy
did not affect their serologic response (Table
4). The proportion of all IBD participants with
serologic protection ranged from 61% to 79%, while
the proportion of those on immunosuppressive
medications ranged from 61% to 81%. Similarly,
serologic protection was mounted in 61% to 100%
of participants who had received age appropriate
vaccines. Therefore, approximately two-fifths of
children with IBD may not have had serologic
protection in spite of completing their vaccination
series.
Only 26 of the 140 participants with the completed
MMR series lacked serologic protection to rubella,
including 15 participants who were currently using
immunosuppressive medications. Participants with
serologic protection for tetanus were older at diagnosis
(median age in years [Q1,Q3]: 14.4 [11.9, 15.6] versus
11.2 [11.7, 9.6], P=0.007). Similarly, 100.0% of
the participants who received the complete tetanus
vaccination before diagnosis mounted serologic
protection compared to those which received the final
dose following diagnosis (82.5%, P=0.01).
For hepatitis B, 150 participants (96.7%) had at
least one known risk factor. Twenty-two (14.2%)
reported a history of packed red blood cell transfusion
with a total number of 29 transfused units (range
1 to 3). Though 114 participants completed the
HBV series, 33 of these participants lacked serologic
protection to HBV. Of the participants with complete
3-dose HBV vaccination series, serologic protection
was mounted by participants with older diagnosis
age (median age in years [Q1,Q3]: 13.7 [11.0, 15.1]
versus 11.6 [8.8, 13.4], P=0.002). In total, 57 of 155
(36.8%) participants lacked serologic protection to
HBV. Fourteen participants either did not receive
or received incomplete HBV vaccine series (not
accounted for by age less than recommended age of
vaccination). In the non-immunized group, potential
risk factors for infection included past history of travel
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outside of Canada (n=49), blood transfusion (n=8),
and body piercing (n=15).
For hepatitis A, 9 participants completed the
HAV series and all mounted serologic protection.
Interestingly, 23 of 137 participants with no prior
HAV vaccination mounted serologic protection to
HAV; although 19 of these participants were born in
Canada, all 23 participants had travelled outside of
Canada.
Discussion
Sixty percent of participants were receiving
immunosuppressive therapy and of these participants
almost three-quarters were also using concomitant
immunosuppressive medications. Immunosuppressive
medications increase the risk of opportunistic
infections; risk is increased by 2 fold with
biologics alone8, 2 to 3 times with corticosteroid
monotherapy, and 15-fold with corticosteroid
and immunomodulator use11. Double or triple
immunosuppressive therapy drastically increases the
risk of opportunistic infections. Clinicians caring
for patients with IBD should ensure appropriate
immunizations are administered and up to date at
time of diagnosis and preceding start of medical
therapy.
Only 69.7% of the participants had the standard
immunizations (MMR, DTap-IPV-Hib, and HBV) up
to date. Nearly a third of individuals in a high-risk
group for more frequent and severe infections had
not received protection against vaccine- preventable
disease. Vaccination coverage ranged from 8.6% for
HAV to 93.4% for MMR and VZV. In general, the
individuals with better access to vaccinations, or
those with less severe disease course had a greater
proportion of the standard immunizations up to date6.
For the individuals with the standard immunizations
up to date, they were in general older at diagnosis
(median age of 12.6 versus 10.5 years) and born
within Canada (94.3%versus 84.8%). The older age
of diagnosis suggests that fewer immunizations may
have been deferred as a result of the onset of the
disease. As well, in general, children born in Canada
have greater accessibility to medical care, increased
awareness of immunizations, and free routine child
immunizations. In comparison, there were several
trends suggesting a more severe disease course in
the individuals who had not received the standard
immunizations. A greater proportion had a history
of medical immunosuppression (84.8% versus 76.4%)
and had received blood transfusions (19.6% versus
10.4%), Medical immunosuppression may have acted
as a deterrent to receiving immunizations, and blood
transfusions often indicate a more severe and acute
disease course.
Ten participants (6.5%) did not have either
previous exposure to the varicella infection or
immunizations. The number of children without
any serologic protection to the varicella virus is
very alarming as infection during immunosuppression
tends to be more serious6. The low proportion
of patients with IBD with up to date vaccinations
in general demonstrates the necessity for medical
staff and caregivers to address the risk of infections
and benefits of immunizations6,7. Adherence to the
recommended immunization schedule is especially
important for those patients who are medically
immunocompromised and at a higher risk of infection.
There was no difference between serologic
protection in individuals who had or had not received
immunosuppressive therapy. The proportion of all
IBD participants with serologic protection ranged
from 61% to 79%, while the proportion of those on
immunosuppressive medications ranged from 61% to
81%. For each specific vaccine, there was at most a
3% difference in proportion of serologic protection,
suggesting that medical immunosuppression
does not affect vaccination efficacy. Another
similar pediatric study determined that patients
receiving immunosuppressive medication, including
2 individuals with IBD among the 25 participants,
found a decreased but insignificant difference in
influenza sero-conversion with the immunocompetent
control group14. On the other hand, a systematic
review that assessed the relationship between
individuals receiving immunosuppressive therapy
and influenza and pneumococcal vaccines identified
a diminished response15. However, this conflict
may be due to the difference in study population.
The participants for both studies included any
patients receiving immunosuppressive therapy;
neither were specific to individuals with IBD like this
study. Therefore, further large cohort studies are
needed to elucidate the effect of immunosuppressive
medications on vaccinations and immunogenic
response in the pediatric IBD population.
A high proportion of individuals received the
completed vaccine series but failed to mount an
appropriate serologic response. Serologic response
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in participants with complete vaccine series ranged
from 63.3% for mumps to 91.8% for tetanus. In
comparison, healthy children aged 1 to 12 years of
age retained varicella vaccine efficacy for up to 10
years (94.4% for one does and 98.3% for two doses,
P < 0.001)16. This marked difference in serologic
response combined with the apparent independence
from immunosuppressive medication status, suggests
that a diagnosis of IBD inherently causes general
immune dysfunction3.
The only vaccine to achieve a 100% immunogenic
response was HAV, as well as an additional 19
individuals who did not receive the HAV vaccinations
but demonstrated serologic immunity. The most
likely explanation is that they were inadvertently
exposed to the virus from traveling outside of
Canada2.
This study was limited by the small sample size
and incomplete immunization data for several of
the participants. Although the goal was to enroll
200 participants, 155 underwent serum collection
and complete vaccination records were available
for 152 participants. This study would have
benefited from a healthy control group that included
children of similar demographics to compare serologic
response to vaccines. On the other hand, this
study is representative of children elsewhere with
similar disease type and treatment, as even though
the data is from a single tertiary-care pediatric
hospital, the participants were managed closely in a
multidisciplinary IBD clinic.
As well, while enrollment was open to children
aged 2 to 18 years old, the majority of participants
were over 12 years old. The immunization schedule
recommends that most children receive the majority
of their vaccines before this age10. Therefore, because
of a small sample size and immunization schedules
for children less than 12 years of age, our findings
should be generalized only to children with IBD over
12 years of age.
The pattern of immunogenicity requires further
elucidation as the results in this study suggest
that medical immunosuppression does not affect the
magnitude and duration of vaccine-induced immunity.
However, previous studies have identified an increased
risk of opportunistic infections for patients with
IBD, especially those on immunosuppressive medical
therapy2,7. In addition, we do not know if differing
vaccination timing relative to immunosuppressive
treatment may alter immunological protection.
Thus, ongoing assessment of the outcomes of
aggressive vaccination in immunosuppressed children
is essential, as is critical revisions to the
recommended vaccination schedule to include booster
shots8. Further studies on the relationship
between vaccine-induced immunity and vaccine
completeness in the pediatric inflammatory bowel
disease population are warranted.
Conclusions
This study provides additional information to
the currently available literature on the use of
vaccinations in children with IBD. Specifically, this
study reinforces the notion that all children with IBD,
regardless of medical immunosuppression, should
adhere to the recommended schedule (aside from
live vaccines) as immunizations decrease the risk of
vaccine-preventable illnesses. Interestingly, serologic
protection was independent of immunosuppressive
therapy, suggesting that a diagnosis of IBD
inherently compromises response to vaccination.
Data suggests that a history of childhood infection
and previous complete immunization does not
guarantee immunogenic protection. If there is any
question as to whether vaccines were administered
or were immunogenic, repeating immunizations is a
recommended and acceptable option11.
The low proportion of participants with complete
up to date immunizations demonstrates the need to
address the risk of infections from vaccine-preventable
disease in patients with IBD, especially those
using immunosuppressive medications. Therefore,
clinicians caring for patients with IBD should be
conscientious about adherence to recommended
vaccination schedules, measurement of immune
response and serologic protection to vaccines, and
booster vaccinations where appropriate.
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